Teamwork Financial Advisors LLC Sells 1,014 Shares of GSK plc (NYSE:GSK)

Teamwork Financial Advisors LLC trimmed its stake in shares of GSK plc (NYSE:GSK) by 14.5% in the fourth quarter, HoldingsChannel.com reports. The fund owned 5,997 shares of the pharmaceutical company’s stock after selling 1,014 shares during the quarter. Teamwork Financial Advisors LLC’s holdings in GSK were worth $222,000 at the end of the most recent reporting period.

A number of other institutional investors have also recently modified their holdings of GSK. Royal Bank of Canada lifted its position in shares of GSK by 255.5% during the 2nd quarter. Royal Bank of Canada now owns 7,690,026 shares of the pharmaceutical company’s stock worth $274,071,000 after buying an additional 5,526,736 shares during the last quarter. Arrowstreet Capital Limited Partnership lifted its position in shares of GSK by 32.5% during the 1st quarter. Arrowstreet Capital Limited Partnership now owns 9,621,370 shares of the pharmaceutical company’s stock worth $419,107,000 after buying an additional 2,362,274 shares during the last quarter. Goldman Sachs Group Inc. lifted its position in shares of GSK by 48.3% during the 1st quarter. Goldman Sachs Group Inc. now owns 7,113,039 shares of the pharmaceutical company’s stock worth $309,844,000 after buying an additional 2,316,204 shares during the last quarter. Nomura Holdings Inc. bought a new stake in shares of GSK during the 4th quarter worth $73,232,000. Finally, Holocene Advisors LP lifted its position in shares of GSK by 146.7% during the 2nd quarter. Holocene Advisors LP now owns 2,917,836 shares of the pharmaceutical company’s stock worth $103,992,000 after buying an additional 1,735,217 shares during the last quarter. 15.74% of the stock is currently owned by institutional investors.

Analyst Upgrades and Downgrades

Several brokerages recently weighed in on GSK. Citigroup upgraded GSK from a “neutral” rating to a “buy” rating in a research report on Tuesday, February 13th. Morgan Stanley initiated coverage on GSK in a research report on Tuesday, January 23rd. They issued an “equal weight” rating for the company. Jefferies Financial Group upgraded GSK from a “hold” rating to a “buy” rating in a research report on Wednesday, January 3rd. Finally, Guggenheim upgraded GSK from a “neutral” rating to a “buy” rating in a research report on Monday, March 4th. One analyst has rated the stock with a sell rating, one has given a hold rating, three have assigned a buy rating and one has issued a strong buy rating to the company. According to data from MarketBeat, GSK currently has an average rating of “Moderate Buy”.

GSK Trading Down 0.3 %

GSK stock traded down $0.12 during trading hours on Friday, hitting $42.87. The stock had a trading volume of 1,854,756 shares, compared to its average volume of 2,612,646. The company has a quick ratio of 0.62, a current ratio of 0.88 and a debt-to-equity ratio of 1.19. The stock has a market cap of $88.24 billion, a price-to-earnings ratio of 14.24, a P/E/G ratio of 1.95 and a beta of 0.64. GSK plc has a one year low of $33.33 and a one year high of $43.84. The business’s 50 day simple moving average is $41.69 and its 200-day simple moving average is $38.38.

GSK (NYSE:GSK) last posted its earnings results on Wednesday, January 31st. The pharmaceutical company reported $0.72 EPS for the quarter, missing the consensus estimate of $0.76 by ($0.04). The firm had revenue of $10 billion during the quarter, compared to the consensus estimate of $9.79 billion. GSK had a net margin of 16.24% and a return on equity of 51.45%. On average, equities analysts predict that GSK plc will post 4.07 EPS for the current fiscal year.

GSK Increases Dividend

The business also recently declared a quarterly dividend, which will be paid on Thursday, April 11th. Stockholders of record on Friday, February 23rd will be paid a $0.3564 dividend. This is a boost from GSK’s previous quarterly dividend of $0.34. The ex-dividend date is Thursday, February 22nd. This represents a $1.43 annualized dividend and a dividend yield of 3.33%. GSK’s dividend payout ratio is presently 52.82%.

GSK Company Profile

GSK plc, together with its subsidiaries, engages in the research, development, and manufacture of vaccines, and specialty and general medicines to prevent and treat disease in the United Kingdom, the United States, and internationally. It operates through two segments, Commercial Operations and Total R&D.